Can The New Cdc Confront The Monkey Pox Challenge

People with monkey pox on isolated background, A person from the back with monkey pox on his body, … [+] Monkey pox virus concept, monkey pox virus epidemic pandemic design getty Yesterday’s announcement by Dr. Rochelle P. Wallensky, the director of the Centers for Disease Control and Prevention (CDC), that the handling of the pandemic was a “failure” from the beginning was too late. Addressing the national monkeypox emergency will give CDC an opportunity to demonstrate its determination to better handle public health challenges. To succeed, the CDC must directly address the weaknesses of its pandemic response: letting political pressure supersede scientific guidelines, developing flawed test kits, failing to release timely pandemic data, publishing confusing and often contradictory messages, and not develop a targeted, coordinated national pandemic strategy. Monkeypox is not new, but the reason for its current resurgence has yet to be determined. TPOXX antivirus, developed by SIGA Technologies Inc. (SIGA) for the treatment of smallpox and accumulated in response to the 9/11 attacks. Expanded access to TPOXX is now available as an investigational new drug (EA-IND) for the treatment of monkeypox. However, clinicians face barriers to obtaining TPOXX from the Strategic National Stockpile (SNS). Monkey pox may not be as deadly as SARS-CoV-2, but it is nevertheless a serious and debilitating disease that can at least leave victims with tell-tale disfiguring scars for life. The only test available for monkeypox requires analysis of fluid from skin lesions. The test is more confirmatory rather than diagnostic since the virus has a long incubation period. It may take 4 – 21 days for symptoms to appear after exposure. During this period, the patient unknowingly transmits monkeypox to others. Symptoms are usually flu-like. the rash develops in a few days post the onset of symptoms.

The importance of diagnostics

The CDC must immediately mobilize its resources to develop, manufacture, distribute, and administer a screening diagnostic test for monkeypox, because this is the only way to stop the spread of the disease from susceptible individuals.  A rapid diagnostic test would detect monkeypox virus using undamaged samples (eg, directly from whole blood, urine, etc.) early after exposure.  Failure to develop such a test will turn a national emergency into a national epidemic.
A rapid monkeypox diagnostic test will allow detection immediately after known or probable exposure to an infected person.  With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated.  When treated early, full-blown infections can be reduced. 
As demonstrated with the much more complex mRNA vaccine programs, this could be done in about 90 days.  The advantage of monkeypox is that it is a well-researched virus.  As with all such endeavors, adequate funding is essential.  Monkeypox test developers must have easy access to clinical samples in the form of inactivated virus.  For rapid commercialization, test developers must have clear guidelines leading to commercialization under the Emergency Use Authorization (EUA).  These could easily be modeled after Covid-19 diagnostic platforms.

A screening monkeypox diagnostic test will allow testing immediately after known or possible exposure to an infected person. With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated. When treated early, full-blown infections can be reduced. Few people today are old enough to have suffered the emotional trauma or disfiguring scars of smallpox, so it is just a distant memory. With the CDC announcing a new approach, the monkeypox challenge is a substantial opportunity for a real-world trial to show it’s serious about change. To be truly successful, coordination with industry and other public health agencies will also be critical in addressing the monkeypox emergency. If, however, the “new” CDC fails to rise to the occasion, it will not just be a missed opportunity. It will be a challenge to the organization’s core competencies and will not soon be forgotten.

title: “Can The New Cdc Confront The Monkey Pox Challenge Klmat” ShowToc: true date: “2022-12-05” author: “Lance Tapia”

People with monkey pox on isolated background, A person from the back with monkey pox on his body, … [+] Monkey pox virus concept, monkey pox virus epidemic pandemic design getty Yesterday’s announcement by Dr. Rochelle P. Wallensky, the director of the Centers for Disease Control and Prevention (CDC), that the handling of the pandemic was a “failure” from the beginning was too late. Addressing the national monkeypox emergency will give CDC an opportunity to demonstrate its determination to better handle public health challenges. To succeed, the CDC must directly address the weaknesses of its pandemic response: letting political pressure supersede scientific guidelines, developing flawed test kits, failing to release timely pandemic data, publishing confusing and often contradictory messages, and not develop a targeted, coordinated national pandemic strategy. Monkeypox is not new, but the reason for its current resurgence has yet to be determined. TPOXX antivirus, developed by SIGA Technologies Inc. (SIGA) for the treatment of smallpox and accumulated in response to the 9/11 attacks. Expanded access to TPOXX is now available as an investigational new drug (EA-IND) for the treatment of monkeypox. However, clinicians face barriers to obtaining TPOXX from the Strategic National Stockpile (SNS). Monkey pox may not be as deadly as SARS-CoV-2, but it is nevertheless a serious and debilitating disease that can at least leave victims with tell-tale disfiguring scars for life. The only test available for monkeypox requires analysis of fluid from skin lesions. The test is more confirmatory rather than diagnostic since the virus has a long incubation period. It may take 4 – 21 days for symptoms to appear after exposure. During this period, the patient unknowingly transmits monkeypox to others. Symptoms are usually flu-like. the rash develops in a few days post the onset of symptoms.

The importance of diagnostics

The CDC must immediately mobilize its resources to develop, manufacture, distribute, and administer a screening diagnostic test for monkeypox, because this is the only way to stop the spread of the disease from susceptible individuals.  A rapid diagnostic test would detect monkeypox virus using undamaged samples (eg, directly from whole blood, urine, etc.) early after exposure.  Failure to develop such a test will turn a national emergency into a national epidemic.
A rapid monkeypox diagnostic test will allow detection immediately after known or probable exposure to an infected person.  With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated.  When treated early, full-blown infections can be reduced. 
As demonstrated with the much more complex mRNA vaccine programs, this could be done in about 90 days.  The advantage of monkeypox is that it is a well-researched virus.  As with all such endeavors, adequate funding is essential.  Monkeypox test developers must have easy access to clinical samples in the form of inactivated virus.  For rapid commercialization, test developers must have clear guidelines leading to commercialization under the Emergency Use Authorization (EUA).  These could easily be modeled after Covid-19 diagnostic platforms.

A screening monkeypox diagnostic test will allow testing immediately after known or possible exposure to an infected person. With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated. When treated early, full-blown infections can be reduced. Few people today are old enough to have suffered the emotional trauma or disfiguring scars of smallpox, so it is just a distant memory. With the CDC announcing a new approach, the monkeypox challenge is a substantial opportunity for a real-world trial to show it’s serious about change. To be truly successful, coordination with industry and other public health agencies will also be critical in addressing the monkeypox emergency. If, however, the “new” CDC fails to rise to the occasion, it will not just be a missed opportunity. It will be a challenge to the organization’s core competencies and will not soon be forgotten.

title: “Can The New Cdc Confront The Monkey Pox Challenge Klmat” ShowToc: true date: “2022-10-21” author: “Cody Walker”

People with monkey pox on isolated background, A person from the back with monkey pox on his body, … [+] Monkey pox virus concept, monkey pox virus epidemic pandemic design getty Yesterday’s announcement by Dr. Rochelle P. Wallensky, the director of the Centers for Disease Control and Prevention (CDC), that the handling of the pandemic was a “failure” from the beginning was too late. Addressing the national monkeypox emergency will give CDC an opportunity to demonstrate its determination to better handle public health challenges. To succeed, the CDC must directly address the weaknesses of its pandemic response: letting political pressure supersede scientific guidelines, developing flawed test kits, failing to release timely pandemic data, publishing confusing and often contradictory messages, and not develop a targeted, coordinated national pandemic strategy. Monkeypox is not new, but the reason for its current resurgence has yet to be determined. TPOXX antivirus, developed by SIGA Technologies Inc. (SIGA) for the treatment of smallpox and accumulated in response to the 9/11 attacks. Expanded access to TPOXX is now available as an investigational new drug (EA-IND) for the treatment of monkeypox. However, clinicians face barriers to obtaining TPOXX from the Strategic National Stockpile (SNS). Monkey pox may not be as deadly as SARS-CoV-2, but it is nevertheless a serious and debilitating disease that can at least leave victims with tell-tale disfiguring scars for life. The only test available for monkeypox requires analysis of fluid from skin lesions. The test is more confirmatory rather than diagnostic since the virus has a long incubation period. It may take 4 – 21 days for symptoms to appear after exposure. During this period, the patient unknowingly transmits monkeypox to others. Symptoms are usually flu-like. the rash develops in a few days post the onset of symptoms.

The importance of diagnostics

The CDC must immediately mobilize its resources to develop, manufacture, distribute, and administer a screening diagnostic test for monkeypox, because this is the only way to stop the spread of the disease from susceptible individuals.  A rapid diagnostic test would detect monkeypox virus using undamaged samples (eg, directly from whole blood, urine, etc.) early after exposure.  Failure to develop such a test will turn a national emergency into a national epidemic.
A rapid monkeypox diagnostic test will allow detection immediately after known or probable exposure to an infected person.  With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated.  When treated early, full-blown infections can be reduced. 
As demonstrated with the much more complex mRNA vaccine programs, this could be done in about 90 days.  The advantage of monkeypox is that it is a well-researched virus.  As with all such endeavors, adequate funding is essential.  Monkeypox test developers must have easy access to clinical samples in the form of inactivated virus.  For rapid commercialization, test developers must have clear guidelines leading to commercialization under the Emergency Use Authorization (EUA).  These could easily be modeled after Covid-19 diagnostic platforms.

A screening monkeypox diagnostic test will allow testing immediately after known or possible exposure to an infected person. With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated. When treated early, full-blown infections can be reduced. Few people today are old enough to have suffered the emotional trauma or disfiguring scars of smallpox, so it is just a distant memory. With the CDC announcing a new approach, the monkeypox challenge is a substantial opportunity for a real-world trial to show it’s serious about change. To be truly successful, coordination with industry and other public health agencies will also be critical in addressing the monkeypox emergency. If, however, the “new” CDC fails to rise to the occasion, it will not just be a missed opportunity. It will be a challenge to the organization’s core competencies and will not soon be forgotten.

title: “Can The New Cdc Confront The Monkey Pox Challenge Klmat” ShowToc: true date: “2022-11-25” author: “Anthony Butler”

People with monkey pox on isolated background, A person from the back with monkey pox on his body, … [+] Monkey pox virus concept, monkey pox virus epidemic pandemic design getty Yesterday’s announcement by Dr. Rochelle P. Wallensky, the director of the Centers for Disease Control and Prevention (CDC), that the handling of the pandemic was a “failure” from the beginning was too late. Addressing the national monkeypox emergency will give CDC an opportunity to demonstrate its determination to better handle public health challenges. To succeed, the CDC must directly address the weaknesses of its pandemic response: letting political pressure supersede scientific guidelines, developing flawed test kits, failing to release timely pandemic data, publishing confusing and often contradictory messages, and not develop a targeted, coordinated national pandemic strategy. Monkeypox is not new, but the reason for its current resurgence has yet to be determined. TPOXX antivirus, developed by SIGA Technologies Inc. (SIGA) for the treatment of smallpox and accumulated in response to the 9/11 attacks. Expanded access to TPOXX is now available as an investigational new drug (EA-IND) for the treatment of monkeypox. However, clinicians face barriers to obtaining TPOXX from the Strategic National Stockpile (SNS). Monkey pox may not be as deadly as SARS-CoV-2, but it is nevertheless a serious and debilitating disease that can at least leave victims with tell-tale disfiguring scars for life. The only test available for monkeypox requires analysis of fluid from skin lesions. The test is more confirmatory rather than diagnostic since the virus has a long incubation period. It may take 4 – 21 days for symptoms to appear after exposure. During this period, the patient unknowingly transmits monkeypox to others. Symptoms are usually flu-like. the rash develops in a few days post the onset of symptoms.

The importance of diagnostics

The CDC must immediately mobilize its resources to develop, manufacture, distribute, and administer a screening diagnostic test for monkeypox, because this is the only way to stop the spread of the disease from susceptible individuals.  A rapid diagnostic test would detect monkeypox virus using undamaged samples (eg, directly from whole blood, urine, etc.) early after exposure.  Failure to develop such a test will turn a national emergency into a national epidemic.
A rapid monkeypox diagnostic test will allow detection immediately after known or probable exposure to an infected person.  With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated.  When treated early, full-blown infections can be reduced. 
As demonstrated with the much more complex mRNA vaccine programs, this could be done in about 90 days.  The advantage of monkeypox is that it is a well-researched virus.  As with all such endeavors, adequate funding is essential.  Monkeypox test developers must have easy access to clinical samples in the form of inactivated virus.  For rapid commercialization, test developers must have clear guidelines leading to commercialization under the Emergency Use Authorization (EUA).  These could easily be modeled after Covid-19 diagnostic platforms.

A screening monkeypox diagnostic test will allow testing immediately after known or possible exposure to an infected person. With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated. When treated early, full-blown infections can be reduced. Few people today are old enough to have suffered the emotional trauma or disfiguring scars of smallpox, so it is just a distant memory. With the CDC announcing a new approach, the monkeypox challenge is a substantial opportunity for a real-world trial to show it’s serious about change. To be truly successful, coordination with industry and other public health agencies will also be critical in addressing the monkeypox emergency. If, however, the “new” CDC fails to rise to the occasion, it will not just be a missed opportunity. It will be a challenge to the organization’s core competencies and will not soon be forgotten.

title: “Can The New Cdc Confront The Monkey Pox Challenge Klmat” ShowToc: true date: “2022-11-19” author: “Maurice Raines”

People with monkey pox on isolated background, A person from the back with monkey pox on his body, … [+] Monkey pox virus concept, monkey pox virus epidemic pandemic design getty Yesterday’s announcement by Dr. Rochelle P. Wallensky, the director of the Centers for Disease Control and Prevention (CDC), that the handling of the pandemic was a “failure” from the beginning was too late. Addressing the national monkeypox emergency will give CDC an opportunity to demonstrate its determination to better handle public health challenges. To succeed, the CDC must directly address the weaknesses of its pandemic response: letting political pressure supersede scientific guidelines, developing flawed test kits, failing to release timely pandemic data, publishing confusing and often contradictory messages, and not develop a targeted, coordinated national pandemic strategy. Monkeypox is not new, but the reason for its current resurgence has yet to be determined. TPOXX antivirus, developed by SIGA Technologies Inc. (SIGA) for the treatment of smallpox and accumulated in response to the 9/11 attacks. Expanded access to TPOXX is now available as an investigational new drug (EA-IND) for the treatment of monkeypox. However, clinicians face barriers to obtaining TPOXX from the Strategic National Stockpile (SNS). Monkey pox may not be as deadly as SARS-CoV-2, but it is nevertheless a serious and debilitating disease that can at least leave victims with tell-tale disfiguring scars for life. The only test available for monkeypox requires analysis of fluid from skin lesions. The test is more confirmatory rather than diagnostic since the virus has a long incubation period. It may take 4 – 21 days for symptoms to appear after exposure. During this period, the patient unknowingly transmits monkeypox to others. Symptoms are usually flu-like. the rash develops in a few days post the onset of symptoms.

The importance of diagnostics

The CDC must immediately mobilize its resources to develop, manufacture, distribute, and administer a screening diagnostic test for monkeypox, because this is the only way to stop the spread of the disease from susceptible individuals.  A rapid diagnostic test would detect monkeypox virus using undamaged samples (eg, directly from whole blood, urine, etc.) early after exposure.  Failure to develop such a test will turn a national emergency into a national epidemic.
A rapid monkeypox diagnostic test will allow detection immediately after known or probable exposure to an infected person.  With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated.  When treated early, full-blown infections can be reduced. 
As demonstrated with the much more complex mRNA vaccine programs, this could be done in about 90 days.  The advantage of monkeypox is that it is a well-researched virus.  As with all such endeavors, adequate funding is essential.  Monkeypox test developers must have easy access to clinical samples in the form of inactivated virus.  For rapid commercialization, test developers must have clear guidelines leading to commercialization under the Emergency Use Authorization (EUA).  These could easily be modeled after Covid-19 diagnostic platforms.

A screening monkeypox diagnostic test will allow testing immediately after known or possible exposure to an infected person. With contact tracing (as already used in Europe), preclinical infections will be identified and treatment will be initiated. When treated early, full-blown infections can be reduced. Few people today are old enough to have suffered the emotional trauma or disfiguring scars of smallpox, so it is just a distant memory. With the CDC announcing a new approach, the monkeypox challenge is a substantial opportunity for a real-world trial to show it’s serious about change. To be truly successful, coordination with industry and other public health agencies will also be critical in addressing the monkeypox emergency. If, however, the “new” CDC fails to rise to the occasion, it will not just be a missed opportunity. It will be a challenge to the organization’s core competencies and will not soon be forgotten.